ESAIY Overview

• Announcement of New Treatment: A new application for the treatment of advanced ROS1-positive non-small cell lung cancer has been validated by the European Medicines Agency.

• Significance of Validation: This validation marks a significant step forward in the marketing authorization process for a promising cancer therapy.

• HSBC Downgrade of Biogen: HSBC downgraded Biogen Inc. (NASDAQ:BIIB) from Hold to Reduce, lowering its price target to $143 due to concerns over reliance on royalty streams and challenges in its core business, which may impact future earnings and growth.

• Recent Developments in Alzheimer's Therapy: Biogen's Alzheimer’s therapy, LEQEMBI, was added to China's Commercial Insurance Innovative Drug List, potentially expanding market access and patient coverage starting January 1, 2026, supported by positive clinical data presented at scientific meetings.

• Progress in Rare Neurological Disorders: Biogen and Stoke Therapeutics showcased long-term data for zorevunersen, an investigational treatment for Dravet syndrome, indicating durable seizure reductions and progress in addressing rare neurological disorders.

• Investment Perspective: Despite Biogen's clinical advancements, HSBC suggests that these may not sufficiently offset broader structural challenges, leading to a belief that some AI stocks may offer better investment potential than BIIB.

• Lecanemab Treatment Findings: Recent data presented at the CTAD conference indicates that continued treatment with lecanemab (Leqembi®) can delay the progression of Alzheimer's disease by up to 8.3 years in patients with low amyloid levels who start treatment early.

• Subcutaneous Formulation Approval: A new subcutaneous formulation of lecanemab, approved for maintenance treatment in the U.S. in August 2025, shows similar efficacy and safety to intravenous dosing, with a low incidence of systemic infusion reactions.

• Long-term Benefits of Early Treatment: Analysis from clinical studies suggests that early initiation of lecanemab treatment can significantly slow disease progression, with time savings of up to 6.0 years from mild cognitive impairment to mild Alzheimer's and 8.3 years to moderate Alzheimer's in low-amyloid patients.

• Collaboration and Commercialization: BioArctic and Eisai have a long-standing partnership for the development and commercialization of lecanemab, with BioArctic retaining rights for commercialization in the Nordic region while Eisai handles global regulatory and market approval processes.

• LEQEMBI Treatment Benefits: Long-term treatment with LEQEMBI may delay the progression of Alzheimer's disease from Mild Cognitive Impairment (MCI) to moderate stages by up to 8.3 years, particularly in patients with low amyloid levels who start treatment early.

• Subcutaneous Formulation: New data presented at the CTAD Conference indicates that a subcutaneous formulation of LEQEMBI maintains similar efficacy and safety to intravenous administration, with a low incidence of systemic infusion reactions.

• Clinical Trial Findings: Analysis from clinical studies suggests that early initiation of LEQEMBI treatment can significantly slow disease progression, with time savings of up to 6 years in low-amyloid patients compared to untreated groups.

• Safety Considerations: LEQEMBI is associated with risks of Amyloid-Related Imaging Abnormalities (ARIA), particularly in ApoE ε4 homozygotes, necessitating careful monitoring and consideration of patient history before treatment initiation.

• Medicare Premium Increase: Medicare Part B premiums will rise by 9.7% in 2026, increasing from $185.00 to $202.90 per month.
• Reasons for Increase: The hike is attributed to medical inflation and a growing number of individuals requiring expensive healthcare services.

FDA Recommendations for Alzheimer's Drug Monitoring

• Earlier Brain Imaging Scans: The FDA has advised that brain imaging scans should be conducted earlier to monitor for brain swelling before the third infusion of the Alzheimer's drug Leqembi, developed by Eisai and Biogen. This is aimed at detecting amyloid-related imaging abnormalities with edema (ARIA-E), which can indicate brain swelling or fluid accumulation.

• Response to Serious Outcomes: This recommendation comes in light of six reported deaths occurring early in the treatment, which prompted a thorough review of serious and fatal outcomes associated with ARIA-E prior to the fifth infusion of Leqembi.

• Updated MRI Scan Guidelines: Previously, the prescribing information for Leqembi required MRI scans before the fifth, seventh, and fourteenth infusions. The FDA now mandates an update to include an MRI scan between the second and third infusions to enhance patient safety.